Business Context and Reporting Period
Company: BioLineRx Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2013
Business Overview: BioLineRx is a clinical-stage biopharmaceutical development company incorporated in Israel. The company focuses on identifying, in-licensing, and developing therapeutic candidates for unmet medical needs. As of the reporting date, the pipeline consisted of six clinical-stage candidates (BL-1040, BL-8040, BL-7010, BL-5010, BL-7040, BL-8020) and three preclinical candidates. The company has no commercial products and generates revenue primarily through milestone payments and royalties from out-licensing arrangements.
Key Financial Metrics
Note: Financial data is presented in thousands of New Israeli Shekels (NIS) and U.S. Dollars (USD) based on the exchange rate of NIS 3.471 per USD as of December 31, 2013.
| Metric | 2013 (NIS) | 2013 (USD) | 2012 (NIS) |
|---|---|---|---|
| Revenues | 0 | 0 | 0 |
| Research & Development Expenses | (44,057) | (12,692) | (64,304) |
| Sales & Marketing Expenses | (4,101) | (1,182) | (3,227) |
| General & Administrative Expenses | (13,225) | (3,810) | (14,026) |
| Operating Loss | (61,383) | (17,684) | (81,557) |
| Net Loss | (61,438) | (17,700) | (76,270) |
| Loss Per Share (Basic) | (0.27) | (0.08) | (0.45) |
| Cash & Cash Equivalents | 30,888 | 8,889 | 68,339 |
| Short-term Bank Deposits | 32,345 | 9,139 | 11,459 |
| Total Cash & Investments | 63,233 | 18,228 | 79,798 |
| Total Assets | 69,469 | 20,015 | 90,808 |
| Total Liabilities | 28,783 | 8,293 | 34,879 |
| Shareholders' Equity | 40,686 | 11,722 | 55,929 |
Material Changes vs. Prior Period
- Revenue: The company recorded zero revenue for both 2013 and 2012. Previous revenue was generated from milestone payments in prior years (2009-2010).
- Operating Loss: The operating loss improved significantly to NIS 61.4 million in 2013 from NIS 81.6 million in 2012. This 25% reduction was primarily driven by a decrease in Research and Development (R&D) expenses.
- R&D Expenses: R&D expenses decreased by 31% (NIS 20.2 million) year-over-year. This reduction was largely due to the termination of the CLARITY clinical trial for the BL-1020 candidate in March 2013, which eliminated significant costs associated with that program. This was partially offset by increased spending on other clinical-stage projects.
- Liquidity: Total cash and short-term investments decreased from approximately NIS 79.8 million in 2012 to NIS 63.2 million in 2013. Net cash used in operating activities was NIS 70.5 million in 2013, a decrease from NIS 75.1 million in 2012.
- Capital Structure: In March 2014 (subsequent to the reporting period), the company closed an underwritten public offering of ADSs for gross proceeds of $24.1 million.
Guidance, Outlook, and Risks
Outlook and Capital Resources: Management believes that existing cash and investment balances (approximately $18.2 million as of Dec 31, 2013), combined with the $24.1 million raised in March 2014, will be sufficient to meet capital requirements through the end of 2016. The company expects to continue incurring operating losses as it advances its therapeutic candidates. Future funding may be required through public/private equity offerings, debt financing, or out-licensing arrangements.
Key Risks and Contingencies:
- Development Risk: As a clinical-stage company, BioLineRx faces significant risks regarding the safety and efficacy of its candidates. Failure in clinical trials could halt development and prevent commercialization.
- Liquidity Risk: The company has a history of losses and an accumulated deficit of approximately NIS 505.8 million. There is no assurance that additional financing will be available on acceptable terms if needed.
- Regulatory Risk: Approval by the FDA and other global regulatory bodies is required for commercialization. Delays or rejections could materially impact the business.
- Out-Licensing Dependence: The company relies on partners (e.g., Bellerophon for BL-1040) to fund and execute clinical development and commercialization. Failure of partners to meet obligations could delay revenue generation.
- Intellectual Property: The company relies on in-licensed technology. Termination of these agreements or failure to secure patent protection could jeopardize the pipeline.
- Geopolitical Risk: Operations are based in Israel, exposing the company to regional political and military instability, which could disrupt operations or affect employee availability due to military reserve duty.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $18.2 million cash balance (plus the $24.1 million March 2014 raise) to fund operations through 2016 given the burn rate.
- BL-1040 Milestones: Confirm the status of the PRESERVATION 1 trial conducted by partner Bellerophon, as future revenue is contingent on regulatory and commercial milestones (up to $265.5 million potential).
- BL-8040 Progress: Review the Phase 2 trial results for Acute Myeloid Leukemia (AML) and the initiation of the stem cell mobilization trial, as these are key near-term catalysts.
- BL-1020 Termination: Understand the full financial impact of terminating the BL-1020 program and the write-off of associated costs.
- Government Grants: Assess the terms of funding received from the Israeli Office of the Chief Scientist (OCS), including potential repayment obligations if products are manufactured outside Israel.
- Warrant Liabilities: Review the fair value adjustments of derivative liabilities (warrants) which impacted non-operating income/expense and could affect future earnings volatility.